CD73 Is Critical for the Resolution of Murine Colonic Inflammation

被引:43
|
作者
Bynoe, Margaret S. [1 ]
Waickman, Adam T. [1 ]
Mahamed, Deeqa A. [1 ]
Mueller, Cynthia [1 ]
Mills, Jeffrey H. [1 ]
Czopik, Agnieszka [2 ]
机构
[1] Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA
[2] MIT, Dept Biol, Cambridge, MA 02139 USA
基金
美国国家卫生研究院;
关键词
NF-KAPPA-B; T-CELLS; INTESTINAL INFLAMMATION; ADENOSINE RECEPTORS; EPITHELIAL BARRIER; BOWEL-DISEASE; PERMEABILITY; COLITIS; ALPHA; SUSCEPTIBILITY;
D O I
10.1155/2012/260983
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
CD73 is a glycosyl-phosphatidylinositol-(GPI-) linked membrane protein that catalyzes the extracellular dephosphorylation of adenosine monophosphate (AMP) to adenosine. Adenosine is a negative regulator of inflammation and prevents excessive cellular damage. We investigated the role of extracellular adenosine in the intestinal mucosa during the development of Dextran-Sulfate-Sodium-(DSS-) salt-induced colitis in mice that lack CD73 (CD73(-/-)) and are unable to synthesize extracellular adenosine. We have found that, compared to wild-type (WT) mice, CD73(-/-) mice are highly susceptible to DSS-induced colitis. CD73(-/-) mice exhibit pronounced weight loss, slower weight recovery, an increase in gut permeability, a decrease in expression of tight junctional adhesion molecules, as well as unresolved inflammation following the removal of DSS. Moreover, colonic epithelia in CD73(-/-) mice exhibited increased TLR9 expression, high levels of IL-1 beta and TNF-alpha, and constitutive activation of NF-kappa B. We conclude that CD73 expression in the colon is critical for regulating the magnitude and the resolution of colonic immune responses.
引用
下载
收藏
页数:13
相关论文
共 50 条
  • [41] Musculoskeletal Manifestations in Patients with CD73 Deficiency
    Cudrici, Cornelia
    Newman, Kam
    Lakshmipathy, Deepak
    Ferrante, Elisa
    Stutler, Rebecca Huff
    Carney, Katherine
    Betancourt, Blas
    Miettinen, Markku
    Katz, James
    Nesti, Leon
    Wen, Han
    Boehm, Manfred
    Brofferio, Alessandra
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [42] An Exceptionally Potent Inhibitor of Human CD73
    Bowman, Christine E.
    da Silva, Rafael G.
    Pham, Amber
    Young, Stephen W.
    BIOCHEMISTRY, 2019, 58 (31) : 3331 - 3334
  • [43] CD73: A Novel Target for Cancer Immunotherapy
    Zhang, Bin
    CANCER RESEARCH, 2010, 70 (16) : 6407 - 6411
  • [44] CD73 Deficiency and Peripheral Artery Calcification
    Chu, Claire
    Moorhead, William J.
    Callahan, John
    Boufford, Camille K.
    Sur, Swastika
    MacTaggart, Jason N.
    Kamenskiy, Alexey
    St Hilaire, Cynthia
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39
  • [45] Targeting CD73 to augment cancer immunotherapy
    Roh, Meejeon
    Wainwright, Derek A.
    Wu, Jennifer D.
    Wan, Yong
    Zhang, Bin
    CURRENT OPINION IN PHARMACOLOGY, 2020, 53 : 66 - 76
  • [46] CD73: an emerging checkpoint for cancer immunotherapy
    Chen, Siqi
    Wainwright, Derek A.
    Wu, Jennifer D.
    Wan, Yong
    Matei, Daniela E.
    Zhang, Yi
    Zhang, Bin
    IMMUNOTHERAPY, 2019, 11 (11) : 983 - 997
  • [47] CD73, a significant protein in liver diseases
    Shi, Huilian
    Dai, Heng
    Sun, Qianqian
    Wang, Siliang
    Chen, Yuanyuan
    FRONTIERS IN MEDICINE, 2023, 10
  • [48] CD73: Friend or Foe in Lung Injury
    Hu, Xiu-Min
    Shi, Nan-Rui
    Zhang, Ji-Zhou
    Zuo, Yan-Qin
    Wang, Xin
    Zhao, Ya-Fei
    Wu, Jia-Si
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [49] CD73: a key player in HIV persistence
    Sperber, H. S.
    Fandrey, J.
    Dittmer, U.
    Esser, S.
    Pillai, S. K.
    Winning, S.
    Schwarzer, R.
    HIV MEDICINE, 2023, 24 : 95 - 95
  • [50] CD73 as a potential opportunity for cancer immunotherapy
    Ghalamfarsa, Ghasem
    Kazemi, Mohammad Hossein
    Mohseni, Sahar Raoofi
    Masjedi, Ali
    Hojjat-Farsangi, Mohammad
    Azizi, Gholamreza
    Yousefi, Mehdi
    Jadidi-Niaragh, Farhad
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (02) : 127 - 142